When was Eikonoklastes founded?

Eikonoklastes was founded in 2019 and raised its 1st funding round 2 years after it was founded.

Where is Eikonoklastes located?

Eikonoklastes is headquartered in Columbus, United States.

How many employees does Eikonoklastes have?

As of Dec 31, 2021, the latest employee count at Eikonoklastes is 3.

Is Eikonoklastes a funded company?

Eikonoklastes is a funded company, having raised a total of $23M across 5 funding rounds to date. The company's 1st funding round was a $***** Series A round, raised on Jun 28, 2021.

When was the latest funding round of Eikonoklastes?

Eikonoklastes' latest funding was a $***** Series B round on Jul 17, 2025, with participation from 0 investor. Its primary sector is Neurology. In United States, the Neurology sector has seen $2.03B in funding in 2026 to date.

Where does Eikonoklastes rank among its competitors?

Eikonoklastes ranks 74th amongst 449 active competitors, of which 155 are funded. It stands 9th in terms of total funding among its competitors. The most recent competitor to raise funding was Mission Therapeutics, which secured $13.3M in Oct, 2025.

Who are the top competitors of Eikonoklastes?

Eikonoklastes' top competitors include Alector, Juvenescence and Annexon. Among them, Mission Therapeutics secured the most recent funding round in October, 2025.

Eikonoklastes - 2026 Company Profile, Team, Funding & Competitors

Eikonoklastes is a series B company based in Columbus (United States), founded in 2019 by Zhiwei Hu and Samuel Lee Md. It operates as a Developer of tissue factor targeting therapeutics to treat cancer. Eikonoklastes has raised $23M in funding from CincyTech. The company has 449 active competitors, including 155 funded and 82 that have exited. Its top competitors include companies like Alector, Juvenescence and Annexon.

Company Details

Developer of tissue factor targeting therapeutics to treat cancer. The company is developing tissue factor targeting therapies that target cell surface receptors for cancers, endometriosis, and other diseases. The company has developed an L-ICON3 platform to create immune therapies engineered with a ligand conjugated to an IgG3 Fc to enable it to bind to cancer cells and treat triple-negative breast cancer. The cells activate complement activation (CDC) and antibody-dependent cellular cytotoxicity (ADCC) to kill cancer cells.

Website: eikonoklastes.com
Email ID: *****@eikonoklastes.com

Key Metrics

Founded Year

2019

Location

Columbus, United States

Stage

Series B

Total Funding

$23M in 5 rounds

Latest Funding Round

Series B, Jul 17, 2025, $*****

Investors

CincyTech & 3 more

Ranked

74^th among 449 active competitors

Employee Count

3 as on Dec 31, 2021

Similar Companies

Alector & 559 more

View Eikonoklastes' full profile

Eikonoklastes has raised a total funding of $23M over 5 rounds. Its first funding round was on Jun 28, 2021. Eikonoklastes has 4 institutional investors.

Here is the list of recent funding rounds of Eikonoklastes:

Filter this list

Date of Funding	Funding Amount	Round Name	Post-Money Valuation	Revenue Multiple	Lead Investors	Other Investors
Jul 17, 2025	2292889	Series B	1872111	5422912	5774160	6596867
Jun 12, 2024	9378391	Series B	4921824	9207087	3684327	1741278
Nov 09, 2023	9455885	Series A	6523463	3862333	9358830	7683461

Access funding benchmarks and valuations. Sign up today!

View details of Eikonoklastes's funding rounds and investors

The founders of Eikonoklastes are Zhiwei Hu and Samuel Lee Md.

Here are the details of Eikonoklastes' key team members:

Zhiwei Hu: Co-Founder of Eikonoklastes.
Contact Info: 1 email address
Samuel Lee Md: Co-Founder, President, and Chief Business Officer of Eikonoklastes.

View details of Eikonoklastes's Founder profiles and Board Members

Eikonoklastes' employee count trend

Eikonoklastes has 3 employees as of Dec 21. Here is Eikonoklastes's employee count trend over the years:

Uncover Eikonoklastes' growth story! Sign up today!

Access Tracxn on any website

Our Google Chrome extension lets you view company details while browsing their websites

Install Tracxn Extension

Top competitors of Eikonoklastes include Alector, Juvenescence and Annexon. Here is the list of Top 10 competitors of Eikonoklastes, ranked by Tracxn score:

Rank	Company Details	Short Description	Total Funding	Investors	Tracxn Score
1st	Alector 2013, San Francisco (United States), Public	Developing immuno-modulatory therapies for dementia and other neurodegenerative disorders	$215M	AbbVie, The Dementia Discovery Fund & 20 others	73/100
2nd	Juvenescence 2017, Dublin (Ireland), Series B	Provider of proprietary ketone ester-based therapeutic drink for age-related disorders and metabolic health	$290M	Ipgl, Foresite Capital & 9 others	68/100
3rd	Annexon 2011, San Francisco (United States), Public	Developer of antibodies to treat complement-mediated neurodegenerative diseases	$256M	Redmile Group, New Enterprise Associates ... & 16 others	67/100
4th	MeiraGTx 2015, New York City (United States), Public	Developer of gene therapies for ocular and neurodegenerative diseases	-	Sanofi, Perceptive Advisors & 5 others	65/100
5th	Axsome Therapeutics 2012, New York City (United States), Public	Developer of therapeutic solutions for the management of CNS disorders	$8.7M	SVB Securities, Collage Venture Partners	65/100
6th	Mission Therapeutics 2011, Cambridge (United Kingdom), Series D	Small molecule drugs that target deubiquitylating enzymes involved in the DNA damage response	$192M	Pfizer Venture Investments, Sofinnova Partners ... & 46 others	63/100
7th	US World Meds 2001, Louisville (United States), Series B	Developer of therapeutics for the treatment of multiple diseases	$149M	Athyrium Capital Management, CRG & 5 others	63/100
8th	Cognition Therapeutics 2007, Pittsburgh (United States), Public	Developer of small molecule drugs for neurodegenerative diseases	$36.1M	Golden Seeds, iNetworks & 28 others	63/100
9th	Blue Rock Therapeutics 2016, Boston (United States), Acquired	Stem cell therapies for cardiovascular and neurological diseases	$225M	Versant Ventures, Leaps by Bayer & 1 others	62/100
10th	Atalanta Therapeutics 2019, Boston (United States), Series B	Developer of RNAi therapeutics to treat neurodegenerative diseases	$262M	F-Prime Capital, Sanofi Ventures & 7 others	62/100
74th	Eikonoklastes 2019, Columbus (United States), Series B	Developer of tissue factor targeting therapeutics to treat cancer	$23M	JobsOhio, Rev1 Ventures & 2 others	50/100